Genomic surveillance to combat COVID-19: challenges and opportunities
- PMID: 34337584
- PMCID: PMC8315763
- DOI: 10.1016/S2666-5247(21)00121-X
Genomic surveillance to combat COVID-19: challenges and opportunities
Abstract
Although the development and increasingly widespread availability of effective and safe vaccines provides the greatest hope for the future recovery from the increasingly devastating COVID-19 pandemic, there are other preventive efforts that offer an immediate route to decreasing morbidity and mortality. Genomic surveillance is emerging as a vital necessity to achieve effective mitigation and containment. Since SARS-CoV-2 variants have already been detected, it is crucial to obtain reliable evidence about whether they are more contagious, virulent, or more resistant to the available COVID-19 vaccines well before they spread throughout the world. Genomic surveillance leverages applications of next-generation sequencing, creates the availability of whole genome data, and advances phylogenetic methods. These methods offer novel means to detect variants that are phenotypically or antigenically different. Genomic surveillance will facilitate greater early anticipation as well as initiation of effective strategies to mitigate and contain outbreaks of SARS-CoV-2 variants and other novel viruses.
© 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.
Conflict of interest statement
DLD reports that he is a consultant to the US National Institutes of Health, the US Food and Drug Administration, and the pharmaceutical and medical device industry on the design, monitoring, and analysis of clinical trials. He receives compensation for serving on several industry sponsored data and safety monitoring committees including AstraZeneca, Amgen, Actelion, Bristol Myers Squibb, DalCor, GlaxoSmithKline, Merck, Sanofi, Boston Scientific, Medtronic, Mesoblast, Intercept, Duke Clinical Research Institute, and Population Health Research Institute of Hamilton. He holds no stock in any pharmaceutical or device company. CHH reports that he serves as an independent scientist in an advisory role to investigators and sponsors as chair of data monitoring committees for Amgen, British Heart Foundation, Cadila, Canadian Institutes of Health Research, DalCor, and Regeneron; serves as an independent scientist in an advisory role to the Collaborative Institutional Training Initiative; serves as legal counsel for Pfizer, the US Food and Drug Administration, and UpToDate; receives royalties for authorship or editorship of three textbooks and as co-inventor on patents for inflammatory markers and cardiovascular disease that are held by Brigham and Women's Hospital; has an investment management relationship with the West-Bacon Group within SunTrust Investment Services, which has discretionary investment authority; and does not own any common or preferred stock in any pharmaceutical or medical device company. All other authors declare no competing interests.
References
-
- Johns Hopkins University & Medicine Tracking—Johns Hopkins University Coronavirus Resource Center. https://coronavirus.jhu.edu/data
-
- Callaway E. The coronavirus is mutating—does it matter? Nature. 2020;585:174–177. - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous